Compare ACM Research Inc (ACMR) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs BridgeBio Pharma Inc — how do they compare? ACM Research Inc trades at $95.79 (market cap $6.54B), while BridgeBio Pharma Inc trades at $77.15 (market cap $15.26B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× ACM Research Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.
| ACMR | BBIO | |
|---|---|---|
Market Cap | $6.54B | $15.26B |
Sector | Technology | Health |
52-Week High | $126.89 | $79.91 |
52-Week Low | $23.92 | $43.19 |
Enterprise Value | $5.61B | $16.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
BridgeBio Pharma (BBIO) trades at $77.91, up 0.93% on the day, supported by a bullish technical outlook and strong analyst consensus. The stock shows robust revenue growth, with 2025 revenue reaching $502.08M, though it remains unprofitable with a net income margin of -124.41%. Recent positive news includes a $1 billion preferred equity raise and regulatory progress for key drug candidates, fueling investor optimism despite ongoing cash burn from operations.
The investment case hinges on the company's pipeline catalysts and commercial execution, with a consensus price target of $102.75 implying significant upside. However, high cash burn, negative equity, and consistent earnings misses present substantial risks, requiring careful monitoring of upcoming clinical and regulatory milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
